Cargando…

Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial

INTRODUCTION: Available therapies for acute cough, a condition frequently caused by a viral upper respiratory tract infection (URTI), have shown limited evidence of efficacy. Gefapixant, a P2X3-receptor antagonist, has demonstrated efficacy and safety in studies of the treatment of refractory or une...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Jaclyn A., Kitt, Michael M., Bell, Alan, Noulin, Nicolas, Tzontcheva, Anjela, Seng, Megan McGratty, Lu, Susan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458823/ https://www.ncbi.nlm.nih.gov/pubmed/35969360 http://dx.doi.org/10.1007/s41030-022-00193-w

Ejemplares similares

Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial
por: Martinez, Fernando J., et al.
Publicado: (2021)

Efficacy of Gefapixant, a P2X(3) Antagonist, for Refractory Atopic Cough
por: Ishiura, Yoshihisa, et al.
Publicado: (2023)

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
por: Muccino, David R., et al.
Publicado: (2020)

Clinical Formulation Bridging of Gefapixant, a P2X3‐Receptor Antagonist, for the Treatment of Chronic Cough
por: Gupta, Pranav, et al.
Publicado: (2022)

Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant
por: Morice, Alyn H., et al.
Publicado: (2021)

Efficacy of gefapixant, a P2X(3) antagonist, for lung cancer-related cough: a case report
por: Ishiura, Yoshihisa, et al.
Publicado: (2023)

Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks
por: Birring, Surinder S., et al.
Publicado: (2023)

Population pharmacokinetic analysis of the P2X3‐receptor antagonist gefapixant
por: Chawla, Akshita, et al.
Publicado: (2023)

Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials
por: Chuang, Min-Hsiang, et al.
Publicado: (2023)

P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough
por: Cui, Wen-Wen, et al.
Publicado: (2022)

Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups
por: Smith, Jaclyn A., et al.
Publicado: (2022)

The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough
por: McGarvey, Lorcan, et al.
Publicado: (2023)

Multilevel modeling for the analysis of longitudinal blood pressure data in the Framingham Heart Study pedigrees
por: Briollais, Laurent, et al.
Publicado: (2003)

Safety and efficacy of gefapixant, a novel drug for the treatment of chronic cough: A systematic review and meta-analysis of randomized controlled trials
por: Abu-Zaid, Ahmed, et al.
Publicado: (2021)

Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans
por: Nussbaum, Jesse C., et al.
Publicado: (2022)

Assessment of Pharmacokinetic Interaction Between Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin
por: McCrea, Jacqueline B., et al.
Publicado: (2021)

Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study
por: Morice, Alyn, et al.
Publicado: (2021)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough
por: McGarvey, Lorcan, et al.
Publicado: (2022)

Effectiveness of a Chinese herbal medicine preparation in the treatment of cough in uncomplicated upper respiratory tract infection: a randomised double-blinded placebo-control trial
por: WCW, Wong, et al.
Publicado: (2006)

Health Tract, No. 230: Cough
Publicado: (1865)

Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study
por: Dicpinigaitis, Peter V., et al.
Publicado: (2023)

Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: a prospective cohort study
por: Nottage, Michelle K, et al.
Publicado: (2006)

PAciFy Cough—a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis Cough
por: Wu, Zhe, et al.
Publicado: (2022)

Cough hypersensitivity and chronic cough
por: Chung, Kian Fan, et al.
Publicado: (2022)

Capsaicin-sensitive cough receptors in lower airway are responsible for cough hypersensitivity in patients with upper airway cough syndrome
por: Yu, Li, et al.
Publicado: (2013)

Cough and its importance in COPD
por: Smith, Jaclyn, et al.
Publicado: (2006)

Chronic cough related to the upper airway cough syndrome: one entity but not always the same
por: Dąbrowska, Marta, et al.
Publicado: (2020)

Upper airway cough syndrome in 103 children
por: Gao, Fan, et al.
Publicado: (2019)

Cough induced by airway vibration as a model of airway hyperreactivity in patients with acute upper respiratory tract infection
por: Eccles, R., et al.
Publicado: (2004)

Randomised trial of the P2X(3) receptor antagonist sivopixant for refractory chronic cough
por: Niimi, Akio, et al.
Publicado: (2022)

What the Placebo Tells Us about Chronic Cough
por: Weinberger, Miles
Publicado: (2023)

Viral Upper Respiratory Tract Infections
por: Guibas, George V., et al.
Publicado: (2017)

Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK)
por: Weinstein, Cindy L J, et al.
Publicado: (2023)

Inhibition of cough reflex sensitivity by diphenhydramine during acute viral respiratory tract infection
por: Dicpinigaitis, Peter V., et al.
Publicado: (2015)

The Powerful Placebo Effect in Cough: Relevance to Treatment and Clinical Trials
por: Eccles, Ron
Publicado: (2019)

Safety And Tolerability Of Extended-Release Guaifenesin In Patients With Cough, Thickened Mucus And Chest Congestion Associated With Upper Respiratory Tract Infection
por: Tripathi, Sanjay, et al.
Publicado: (2019)

Effect of Jiuwei Zhuhuang Powder on Cough Resolution in Children with Upper Respiratory Tract Infections: A Multicenter Randomized Controlled Trial
por: Luo, Hui, et al.
Publicado: (2021)

Trop-2 in Upper Tract Urothelial Carcinoma
por: Tomiyama, Eisuke, et al.
Publicado: (2022)

How often do healthy people cough?
por: Holt, Kimberley J., et al.
Publicado: (2023)

Viral and Bacterial Interactions in the Upper Respiratory Tract
por: Bosch, Astrid A. T. M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ng9aqmdh0mrhmbi6ao99tf8oa9